Dyne Therapeutics annual shareholders’ equity
2019
2020
2021
2022
2023
2024
2025
Dyne Therapeutics Shareholders’ Equity Growth & History (DYN)
Dyne Therapeutics's shareholders’ equity was $972.1M for fiscal 2025.
View full Dyne Therapeutics company overviewDyne Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $972.1M | $342.3M | +54.35% |
| 2024 | 2024-12-31 | $629.8M | $538.5M | +589.92% |
| 2023 | 2023-12-31 | $91.3M | −$161.1M | −63.83% |
| 2022 | 2022-12-31 | $252.4M | −$115.8M | −31.46% |
| 2021 | 2021-12-31 | $368.2M | $25.8M | +7.54% |
| 2020 | 2020-12-31 | $342.4M | $328.3M | +2339.21% |
| 2019 | 2019-12-31 | $14.0M | — | — |
Dyne Therapeutics quarterly shareholders’ equity
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $702.2M | $130.7M | +22.87% |
| Q1 2026 | 2026-03-31 | $865.1M | $196.1M | +29.31% |
| Q4 2025 | 2025-12-31 | $972.1M | $342.3M | +54.35% |
| Q3 2025 | 2025-09-30 | $691.8M | −$13.8M | −1.95% |
| Q2 2025 | 2025-06-30 | $571.4M | −$203.7M | −26.28% |
| Q1 2025 | 2025-03-31 | $669.0M | $190.9M | +39.94% |
| Q4 2024 | 2024-12-31 | $629.8M | $538.5M | +589.92% |
| Q3 2024 | 2024-09-30 | $705.5M | $553.5M | +364.06% |
| Q2 2024 | 2024-06-30 | $775.2M | $568.3M | +274.71% |
| Q1 2024 | 2024-03-31 | $478.1M | $236.1M | +97.60% |
| Q4 2023 | 2023-12-31 | $91.3M | −$161.1M | −63.83% |
| Q3 2023 | 2023-09-30 | $152.0M | −$97.7M | −39.12% |
| Q2 2023 | 2023-06-30 | $206.9M | −$80.2M | −27.93% |
| Q1 2023 | 2023-03-31 | $241.9M | −$94.5M | −28.09% |
| Q4 2022 | 2022-12-31 | $252.4M | −$115.8M | −31.46% |
| Q3 2022 | 2022-09-30 | $249.7M | −$164.4M | −39.69% |
| Q2 2022 | 2022-06-30 | $287.1M | −$165.5M | −36.58% |
| Q1 2022 | 2022-03-31 | $336.5M | −$141.8M | −29.65% |
| Q4 2021 | 2021-12-31 | $368.2M | $25.8M | +7.54% |
| Q3 2021 | 2021-09-30 | $414.1M | $47.3M | +12.89% |
| Q2 2021 | 2021-06-30 | $452.6M | — | — |
| Q1 2021 | 2021-03-31 | $478.3M | — | — |
| Q4 2020 | 2020-12-31 | $342.4M | $328.3M | +2339.21% |
| Q3 2020 | 2020-09-30 | $366.8M | — | — |
| Q4 2019 | 2019-12-31 | $14.0M | — | — |
Dyne Therapeutics shareholders’ equity trends
Over the last five fiscal years, Dyne Therapeutics's shareholders’ equity increased from $342.4M to $972.1M, a change of $629.8M. The latest reported quarter, Q2 2026, shows $702.2M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...